Advertisement

Drugs & Aging

, Volume 36, Issue 2, pp 147–154 | Cite as

Using Lithium in Older Age Bipolar Disorder: Special Considerations

  • Jocelyn Fotso SohEmail author
  • Sivan Klil-Drori
  • Soham Rej
Review Article

Abstract

Lithium is the gold-standard treatment for bipolar disorder, and is effective in the management of manic, depressive, and maintenance phases of bipolar disorder treatment. Despite this, the implications of lithium use in the older population remain less understood. This critical narrative review aims to better understand the impact of lithium in older age bipolar disorder (OABD), including tolerability and efficacy, based on up-to-date evidence. Relevant studies of efficacy, effectiveness, and tolerability published any time prior to May 2018 were identified using the PubMed keyword search “lithium older adult bipolar disorder” and references from recent international bipolar disorder guidelines. One randomized controlled trial was identified, the GERI-BD (Acute Pharmacotherapy in Late-Life Mania) study. This study found lithium to be effective in late-life mania and hypomania. The remaining literature examining lithium in OABD was reviewed, comprising of a number of small open-label and retrospective studies, with special considerations highlighted. In summary, there is a small yet increasing geriatric evidence base that lithium is effective in OABD. Although there can be adverse effects with lithium, it is generally well tolerated, and there are methods to minimize these risks. Further research would strengthen the evidence base for lithium therapy in OABD. In the meantime, lithium remains the gold-standard treatment for OABD.

Notes

Compliance with Ethical Standards

Conflict of interest

Jocelyn Fotso Soh, Sivan Klil-Drori, and Soham Rej have no conflicts of interest to declare. Soham Rej has received an investigator-initiated research grant from Satellite Healthcare for an unrelated project.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

  1. 1.
    Sajatovic M, Strejilevich SA, Gildengers AG, Dols A, Al Jurdi RK, Forester BP, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord. 2015;17(7):689–704.Google Scholar
  2. 2.
    Jeste DV, Alexopoulos GS, Bartels SJ, Cummings JL, Gallo JJ, Gottlieb GL, et al. Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry. 1999;56(9):848–53.Google Scholar
  3. 3.
    Yu C, Sylvestre JD, Segal M, Looper KJ, Rej S. Predictors of psychiatric re-hospitalization in older adults with severe mental illness. Int J Geriatr Psychiatry. 2015;30(11):1114–9.Google Scholar
  4. 4.
    Bartels SJ, Forester B, Miles KM, Joyce T. Mental health service use by elderly patients with bipolar disorder and unipolar major depression. Am J Geriatr Psychiatry. 2000;8(2):160–6.Google Scholar
  5. 5.
    Gildengers AG, Whyte EM, Drayer RA, Soreca I, Fagiolini A, Kilbourne AM, et al. Medical burden in late-life bipolar and major depressive disorders. Am J Geriatr Psychiatry. 2008;16(3):194–200.Google Scholar
  6. 6.
    Lala SV, Sajatovic M. Medical and psychiatric comorbidities among elderly individuals with bipolar disorder: a literature review. J Geriatr Psychiatry Neurol. 2012;25(1):20–5.Google Scholar
  7. 7.
    Forty L, Ulanova A, Jones L, Jones I, Gordon-Smith K, Fraser C, et al. Comorbid medical illness in bipolar disorder. Br J Psychiatry. 2014;205(6):465–72.Google Scholar
  8. 8.
    Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: what do we know? J Affect Disord. 2013;146(2):151–7.Google Scholar
  9. 9.
    Al Jurdi RK, Marangell LB, Petersen NJ, Martinez M, Gyulai L, Sajatovic M. Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a “recovered” status in the systematic treatment enhancement program for bipolar disorder. Am J Geriatr Psychiatry. 2008;16(11):922–33.Google Scholar
  10. 10.
    Dols A, Sienaert P, van Gerven H, Schouws S, Stevens A, Kupka R, et al. The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: a review. Int Clin Psychopharmacol. 2013;28(6):287–96.Google Scholar
  11. 11.
    Young RC, Mulsant BH, Sajatovic M, Gildengers A, Gyulai L, Al Jurdi RK, et al. GERI-BD: a randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry. 2017;174(11):1086–93.Google Scholar
  12. 12.
    Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.Google Scholar
  13. 13.
    Forester BP, Sajatovic M, Tsai J, Kroger H, Pikalov A, Cucchiaro J, et al. Efficacy and safety of long-term treatment with lurasidone in older adults with bipolar depression: results of a 6 month open-label study. Am J Geriatr Psychiatry. 2015;23(3 Suppl):S170–1.Google Scholar
  14. 14.
    Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, et al. Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. J Clin Psychiatry. 2016;77(10):e1324–31.Google Scholar
  15. 15.
    Sajatovic M, Gildengers A, Al Jurdi RK, Gyulai L, Cassidy KA, Greenberg RL, et al. Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report. Bipolar Disord. 2011;13(3):294–302.Google Scholar
  16. 16.
    Robillard M, Conn DK. Lamotrigine use in geriatric patients with bipolar depression. Can J Psychiatry (Revue Can Psychiatr). 2002;47(8):767–70.Google Scholar
  17. 17.
    Sajatovic M, Calabrese JR, Mullen J. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord. 2008;10(6):662–71.Google Scholar
  18. 18.
    Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68(10):1480–91.Google Scholar
  19. 19.
    Baruch Y, Tadger S, Plopski I, Barak Y. Asenapine for elderly bipolar manic patients. J Affect Disord. 2013;145(1):130–2.Google Scholar
  20. 20.
    Sajatovic M, Dines P, Fuentes-Casiano E, Athey M, Cassidy KA, Sams J, et al. Asenapine in the treatment of older adults with bipolar disorder. Int J Geriatr Psychiatry. 2015;30(7):710–9.Google Scholar
  21. 21.
    Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry. 1996;29(3):103–7.Google Scholar
  22. 22.
    Sajatovic M, Strejilevich SA, Gildengers AG, Dols A, Al Jurdi RK, Forester BP, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord. 2015;17(7):689–704.Google Scholar
  23. 23.
    Shulman RW, Singh A, Shulman KI. Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacol Bull. 1997;33(1):113–8.Google Scholar
  24. 24.
    Al Jurdi RK, Marangell LB, Petersen NJ, Martinez M, Gyulai L, Sajatovic M. Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a “recovered” status in the systematic treatment enhancement program for bipolar disorder. Am J Geriatr Psychiatry. 2008;16(11):922–33.Google Scholar
  25. 25.
    Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385–95.Google Scholar
  26. 26.
    Sajatovic M, Gyulai L, Calabrese JR, Thompson TR, Wilson BG, White R, et al. Maintenance treatment outcomes in older patients with bipolar I disorder. Am J Geriatr Psychiatry. 2005;13(4):305–11.Google Scholar
  27. 27.
    Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349–52.Google Scholar
  28. 28.
    Kessing LV, Bauer M, Nolen WA, Severus E, Goodwin GM, Geddes J. Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord.  https://doi.org/10.1111/bdi.12623 (epub 14 Feb 2018).
  29. 29.
    Lahteenvuo M, Tanskanen A, Taipale H, Hoti F, Vattulainen P, Vieta E, et al. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry. 2018;75(4):347–55.Google Scholar
  30. 30.
    Manchia M, Adli M, Akula N, Ardau R, Aubry JM, Backlund L, et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a consortium on lithium genetics (ConLiGen) report. PLoS One. 2013;8(6):e65636.Google Scholar
  31. 31.
    Rej S, Herrmann N, Shulman K, Fischer HD, Fung K, Gruneir A. Current psychotropic medication prescribing patterns in late-life bipolar disorder. Int J Geriatr Psychiatry. 2017;32(12):1459–65.Google Scholar
  32. 32.
    Abou-Saleh MTC. Lithium in the prophylaxis of unipolar depression: a review. J R Soc Med. 1983;76(4):297–301.Google Scholar
  33. 33.
    Himmelhoch JM, Neil JF, May SJ, Fuchs CZ, Licata SM. Age, dementia, dyskinesias, and lithium response. Am J Psychiatry. 1980;137(8):941–5.Google Scholar
  34. 34.
    Murray N, Hopwood S, Balfour DJ, Ogston S, Hewick DS. The influence of age on lithium efficacy and side-effects in out-patients. Psychol Med. 1983;13(1):53–60.Google Scholar
  35. 35.
    Sajatovic M, Bingham CR, Campbell EA, Fletcher DF. Bipolar disorder in older adult inpatients. J Nerv Ment Dis. 2005;193(6):417–9.Google Scholar
  36. 36.
    Sanderson DR. Use of mood stabilizers by hospitalized geriatric patients with bipolar disorder. Psychiatr Serv. 1998;49(9):1145–7.Google Scholar
  37. 37.
    Schaffer CB, Batra K, Garvey MJ, Mungas DM, Schaffer LC. The effect of haloperidol on serum levels of lithium in adult manic patients. Biol Psychiatry. 1984;19(10):1495–9.Google Scholar
  38. 38.
    Sharma AN, Persad E, Mazmanian D, Karunaratne K. Treatment of rapid cycling bipolardisorder with combination therapy of valproate and lithium. Can J Psychiatry (Revue Can Psychiatr). 1993;38(2):137–9.Google Scholar
  39. 39.
    Stone JA. Mania in the elderly. Br J Psychiatry. 1989;155:220–4.Google Scholar
  40. 40.
    Rej S, Herrmann N, Shulman K, Fischer HD, Fung K, Harel Z, et al. Lithium use, but not valproate use, is associated with a higher risk of chronic kidney disease in older adults with mental illness. J Clin Psychiatry. 2017;78(8):e980–5.Google Scholar
  41. 41.
    Shulman KI, Rochon P, Sykora K, Anderson G, Mamdani M, Bronskill S, et al. Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ. 2003;326(7396):960–1.Google Scholar
  42. 42.
    Kessing LV, Gerds TA, Feldt-Rasmussen B, Andersen PK, Licht RW. Use of lithium and anticonvulsants and the rate of chronic kidney disease: a nationwide population-based study. JAMA Psychiatry. 2015;72(12):1182–91.Google Scholar
  43. 43.
    Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015;386(9992):461–8.Google Scholar
  44. 44.
    Kirkham E, Bazire S, Anderson T, Wood J, Grassby P, Desborough JA. Impact of active monitoring on lithium management in Norfolk. Ther Adv Psychopharmacol. 2013;3(5):260–5.Google Scholar
  45. 45.
    Rej S, Herrmann N, Shulman K. The effects of lithium on renal function in older adults: a systematic review. J Geriatr Psychiatry Neurol. 2012;25(1):51–61.Google Scholar
  46. 46.
    Schou M, Amdisen A, Trap-Jensen J. Lithium poisoning. Am J Psychiatry. 1968;125(4):520–7.Google Scholar
  47. 47.
    Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559–95.Google Scholar
  48. 48.
    Juurlink DN, Mamdani MM, Kopp A, Rochon PA, Shulman KI, Redelmeier DA. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc. 2004;52(5):794–8.Google Scholar
  49. 49.
    Lamb EJ. United Kingdom guidelines for chronic kidney disease. Scand J Clin Lab Investig Suppl. 2008;241:16–22.Google Scholar
  50. 50.
    Rej S, AlAqeel B, Segal M, Low NC, Mucsi I, Holcroft C, et al. Is environmental temperature related to renal symptoms, serum lithium levels, and other laboratory test results in current lithium users? Hum Psychopharmacol. 2014;29(4):392–6.Google Scholar
  51. 51.
    Wilting I, Fase S, Martens EP, Heerdink ER, Nolen WA, Egberts AC. The impact of environmental temperature on lithium serum levels. Bipolar Disord. 2007;9(6):603–8.Google Scholar
  52. 52.
    Rej S, Elie D, Mucsi I, Looper KJ, Segal M. Chronic kidney disease in lithium-treated older adults: a review of epidemiology, mechanisms, and implications for the treatment of late-life mood disorders. Drugs Aging. 2015;32(1):31–42.Google Scholar
  53. 53.
    Lewis G, Maxwell AP. Timely diagnosis and treatment essential in glomerulonephritis. Practitioner. 2015;259(1779):13–7.Google Scholar
  54. 54.
    Shulman KI, Sykora K, Gill SS, Mamdani M, Anderson G, Marras C, et al. New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice. Am J Geriatr Psychiatry. 2005;13(4):299–304.Google Scholar
  55. 55.
    Head L, Dening T. Lithium in the over-65 s: who is taking it and who is monitoring it? A survey of older adults on lithium in the Cambridge Mental Health Services catchment area. Int J Geriatr Psychiatry. 1998;13(3):164–71.Google Scholar
  56. 56.
    Dols A, Rhebergen D, Beekman A, Kupka R, Sajatovic M, Stek ML. Psychiatric and medical comorbidities: results from a bipolar elderly cohort study. Am J Geriatr Psychiatry. 2014;22(11):1066–74.Google Scholar
  57. 57.
    Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry. 2008;65(11):1331–5.Google Scholar
  58. 58.
    Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;198(5):351–6.Google Scholar
  59. 59.
    Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences. BMC Med. 2012;10:148.Google Scholar
  60. 60.
    Lan CC, Liu CC, Lin CH, Lan TY, McInnis MG, Chan CH, et al. A reduced risk of stroke with lithium exposure in bipolar disorder: a population-based retrospective cohort study. Bipolar Disord. 2015;17(7):705–14.Google Scholar
  61. 61.
    Zaidan M, Stucker F, Stengel B, Vasiliu V, Hummel A, Landais P, et al. Increased risk of solid renal tumors in lithium-treated patients. Kidney Int. 2014;86(1):184–90.Google Scholar
  62. 62.
    Bosche B, Schafer M, Graf R, Hartel FV, Schafer U, Noll T. Lithium prevents early cytosolic calcium increase and secondary injurious calcium overload in glycolytically inhibited endothelial cells. Biochem Biophys Res Commun. 2013;434(2):268–72.Google Scholar
  63. 63.
    Gold AB, Herrmann N, Lanctot KL. Lithium and its neuroprotective and neurotrophic effects: potential treatment for post-ischemic stroke sequelae. Curr Drug Targets. 2011;12(2):243–55.Google Scholar
  64. 64.
    Trepiccione F, Christensen BM. Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings. J Nephrol. 2010;23(Suppl 16):S43–8.Google Scholar
  65. 65.
    Kishore BK, Ecelbarger CM. Lithium: a versatile tool for understanding renal physiology. Am J Physiol Renal Physiol. 2013;304(9):F1139–49.Google Scholar
  66. 66.
    Gao C, Holscher C, Liu Y, Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci. 2012;23(1):1–11.Google Scholar
  67. 67.
    Jiang Y, McCombs JS, Park SH. A retrospective cohort study of acute kidney injury risk associated with antipsychotics. CNS Drugs. 2017;31(4):319–26.Google Scholar
  68. 68.
    Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014;161(4):242–8.Google Scholar
  69. 69.
    Chen C, Veronese L, Yin Y. The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol. 2000;50(3):193–5.Google Scholar
  70. 70.
    Fung J, Mok H, Yatham LN. Lamotrigine for bipolar disorder: translating research into clinical practice. Expert Rev Neurother. 2004;4(3):363–70.Google Scholar
  71. 71.
    Young RC; GERI-BD Study Group. Lithium and divalproex in the treatment of mania in older patients with bipolar disorder: a randomized clinical trial. American Society of Clinical Psychopharmacology annual meeting, 22 June 2015; Miami.Google Scholar
  72. 72.
    Dols A, Kessing LV, Strejilevich SA, Rej S, Tsai SY, Gildengers AG, et al. Do current national and international guidelines have specific recommendations for older adults with bipolar disorder? A brief report. Int J Geriatr Psychiatry. 2016;31(12):1295–300.Google Scholar
  73. 73.
    Shulman KI, Almeida OP, Herrmann N, Schaffer A, Strejilevich SA, Paternoster C, et al. Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: an ISBD task force report. Bipolar Disord.  https://doi.org/10.1111/bdi.12714 (epub 30 Oct 2018).
  74. 74.
    Sun M, Herrmann N, Shulman KI. Lithium toxicity in older adults: a systematic review of case reports. Clin Drug Investig. 2018;38(3):201–9.Google Scholar
  75. 75.
    Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.Google Scholar
  76. 76.
    Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2:15.Google Scholar
  77. 77.
    Forester BP, Streeter CC, Berlow YA, Tian H, Wardrop M, Finn CT, et al. Brain lithium levels and effects on cognition and mood in geriatric bipolar disorder: a lithium-7 magnetic resonance spectroscopy study. Am J Geriatr Psychiatry. 2009;17(1):13–23.Google Scholar
  78. 78.
    Rej S, Beaulieu S, Segal M, Low NC, Mucsi I, Holcroft C, et al. Lithium dosing and serum concentrations across the age spectrum: from early adulthood to the tenth decade of life. Drugs Aging. 2014;31(12):911–6.Google Scholar
  79. 79.
    Jensen HV, Plenge P, Stensgaard A, Mellerup ET, Thomsen C, Aggernaes H, et al. Twelve-hour brain lithium concentration in lithium maintenance treatment of manic-depressive disorder: daily versus alternate-day dosing schedule. Psychopharmacology (Berl). 1996;124(3):275–8.Google Scholar
  80. 80.
    Kristoff CA, Hayes PE, Barr WH, Small RE, Townsend RJ, Ettigi PG. Effect of ibuprofen on lithium plasma and red blood cell concentrations. Clin Pharm. 1986;5(1):51–5.Google Scholar
  81. 81.
    Reimann IW, Diener U, Frolich JC. Indomethacin but not aspirin increases plasma lithium ion levels. Arch Gen Psychiatry. 1983;40(3):283–6.Google Scholar
  82. 82.
    Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003;64(11):1328–34.Google Scholar
  83. 83.
    Himmelhoch JM, Forrest J, Neil JF, Detre TP. Thiazide-lithium synergy in refractory mood swings. Am J Psychiatry. 1977;134(2):149–52.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Geri-PARTy Research Group, Department of Psychiatry, Jewish General Hospital, Institute of Community and Family PsychiatryMcGill UniversityMontrealCanada
  2. 2.Department of PsychiatryMcGill UniversityMontrealCanada

Personalised recommendations